COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease
Clinical trial NCT05081388 · TERMINATED
Trial details
- NCT number
- NCT05081388
- Sponsor
- Regeneron Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-08
- Primary completion
- 2022-06-30
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.